Special Educational Needs: support in England
An overview of the current system of support for children and young people with special educational needs, and pressure on the system
A Westminster Hall debate on the treatment of lobular breast cancer is scheduled for Tuesday 10 December 2024 at 2.30pm. The debate will be led by Helen Hayes MP.
Treatment of lobular breast cancer (132 KB , PDF)
Lobular breast cancer is a type of breast cancer that starts in the glands that make milk when breastfeeding, known as lobules, and spreads into the surrounding breast tissue. It is also known as invasive lobular breast cancer or invasive lobular carcinoma.
There is a lack of up-to-date data on the number of people diagnosed with lobular breast cancer. The Office for National Statistics has published statistics showing the number of people diagnosed with Lobular Breast Cancer in England each year from 2006 to 2016. According to this data, there were a total of 6765 people diagnosed with lobular breast cancer in 2016: 6754 women and 11 men.
Cancer Research UK has reported that around 15% of all breast cancers are lobular breast cancer.
The charity Lobular Breast Cancer UK has published a list of signs and symptoms of Lobular Breast Cancer:
All women aged from 50 to 71 are invited for breast cancer screening every three years. NHS breast cancer screening uses x-ray scans called mammograms to look for cancers that may be too small to feel.
More information on NHS breast screening can be found on the government website, updated in October 2024.
In September 2024, the government updated guidance on protocols for the surveillance of women at higher risk of developing breast cancer.
Unlike other breast cancers, lobular breast cancer tends to spread out in straight lines rather than amassing to form a firm lump. A person is more likely to have a thickened area of breast tissue as a symptom rather than a lump.
This can make lobular breast cancer difficult to detect in physical examination and when using imaging scans such as mammograms and ultrasound. Whilst lobular breast cancer is slow-growing compared to other cancers, tumours can often be large by the time that the cancer is diagnosed.
Various academic evidence indicates that magnetic resonance imaging (MRI), which can produce detailed images of inside the breast, offers improved detection and characterisation of lobular breast cancer.
There is no national standard treatment or guidelines for patients with lobular breast cancer. It is treated in the same way as more common types of invasive cancer. Treatment will depend on various factors including:
Potential treatment options include:
The National Institute for Health and Care Excellence (NICE) guidelines on early and locally advanced breast cancer and advanced breast cancer sets out recommendations about the diagnosis and management of breast cancer, including lobular breast cancer. In relation to lobular breast cancer in particular, the guidelines on early and locally advanced breast cancer include a specific recommendation to offer an MRI scan before surgery to assess tumour size where breast-conserving surgery is planned (recommendation 1.1.3).
The Lobular Moon Shot Project was set up in 2023. This project aims to raise funds to support research to improve understanding of how lobular breast cancer develops and spreads, to identify new drugs that could be used to treat the condition and to test these in clinical trials. In November 2024, the Lobular Moon Shot Project announced a partnership with the Manchester Breast Centre to help expedite research into Invasive Lobular Breast Cancer.
The European Lobular Breast Cancer Consortium is a network of researchers focused on improving understanding, diagnosis and treatment of the condition.
Several charities, including Lobular Breast Cancer Alliance and Lobular Breast Cancer UK, have highlighted a need for research that focuses on lobular breast cancer and treatment pathways specifically for it.
Some MPs have called for government funding for research for lobular cancer treatment pathways and the government have responded to several parliamentary questions about its activity to support diagnosis, treatment and research for lobular breast cancer. In its responses, the government has highlighted general funding to support cancer research such as £1.5 million for research via the National Institute of Health and Care Research (NIHR) and £29 million to the Institute of Cancer Research and the Royal Marsden NIHR Biological Research Centre. In addition, it has pointed to:
Treatment of lobular breast cancer (132 KB , PDF)
An overview of the current system of support for children and young people with special educational needs, and pressure on the system
A briefing on the licensing, regulation and supply of new weight loss medications in England.
A debate has been scheduled in Westminster Hall for 3pm on 23 January on innovation in the field of rare retinal disease. The subject for the debate has been chosen by the Backbench Business Committee, and the debate will be opened by Jim Shannon MP.